

MARQUETTE GENERAL HOSPITAL
REGIONAL MEDICAL CENTER

ROBERT C. NELDBERG, EXECUTIVE DIRECTOR

January 20, 1988

RECEIVED
'88 FEB -8 A9:25
US NRC
LICENSING SECTION

United States Nuclear Regulatory
Commission
Region III
Materials Licensing Section
700 Roosevelt Road
Glen Ellyn, Illinois 60137

Dear Sirs:

Please ammend our materials license #21-05432-04 to include the following individuals as authorized users for invitro tests only under part 31.11 of 10cFR.

- Dr. Martin Matthews, M.D.
- Dr. John Weiss, M.D.
- Dr. Randolph Smith, M.D.

All of these doctors are currently on staff as clinical pathologist at Marquette General Hospital and I am including letters stating the training they have received during their education.

Enclosed you will also find a check for \$120.00 for this ammendment.

Sincerely,

Ray Wery
Ray F. Wery, Physicist
Radiation Oncology Department
(906) 225-3012
1-800-562-9753, extension 3102

RFW:lsa

Enclosures

Log	<i>Lab 11</i>
Remitter	
Check No.	<i>50577</i>
Amount	<i>120.00</i>
Fee C.	<i>00</i>
Type	<i>and</i>
Dat	
De	
By:	<i>Wery</i>

RECEIVED

FEB 01 1988

REGION III

8902140223 880218
REG3 LIC30
21-05432-04 PNU

CONTROL NO. 84807

FEB 1 1988

MARQUETTE GENERAL HOSPITAL
DEPARTMENT OF PATHOLOGY
420 WEST MAGNETIC ST.
MARQUETTE, MI 49855

DATE: 1-12-88
TO: Ray Wery
FROM: John Weiss *JW*
RE: Previous training/experience in radioisotopes.

I spent a three month rotation on the special chemistry service at the Denver Veterans Administration Hospital as part of my training in Clinical Pathology at the University of Colorado Medical Center. I have no experience with radioisotopes since leaving residency.

cc: files
Randy Smith
Ray Jarvis

CONTROL NO. 84807
• *

12-22-87

To: Ray Wery

From: Randolph Smith, M.D. 

Re: Training in use of radioactive materials. Per your letter
(received 12-21-87).

My background in the use of radioisotopes is as follows:

Spring, 1975. Michigan Technological University. Audited a 4 (quarter) credit undergraduate course-- "Radioisotope Techniques" (BL419), classroom and lab. C-14, I-131, Cs-137, P-32, I-125. Also Atomic Energy of Canada Gamma Cell 200 (Co-60).

Approximately two months of Pathology Residency training (Medical College of Wisconsin Affil. Hosps., 1979-1983) included exposure to in-vitro radioimmunoassay. Covering intermittent "on call problems" added some additional experience. Isotopes were utilized only as supplied in manufacturer's "kits."

1983-present. Director of Special Chemistry, Marquette General Hospital. In vitro radioimmunoassay. "In vivo dilution studies" (RBC survival, RBC mass/Blood volume). Schilling's tests. Cr-51, Co-57, and isotopes supplied in in-vitro RIA "kits."

If you have comments, questions, or desire any clarification, please contact me.

cc: Dale Hamari
Ray Jarvis
Files

CONTROL NO. 84807

MARQUETTE GENERAL HOSPITAL
Regional Medical Center

January 12, 1988

TO: Ray Wery, Physicist
Radiation Oncology Department

FROM: M. Matthews, M.D.
MM

My experience in handling of isotopes consists of one week of observation in an RIA lab during clinical pathology residency at the Geisinger Medical Center in Danville, PA.

During that time, I read over safety procedures, though I did not handle any radioactive material.

MM:lisa

cc: Ray Jarvis
Director of Laboratory

CONTROL NO 84807